Capítulo 6. 6. Fibrinolisis y fármacos trombolíticos


1. Tillet WS, Garner RL.: The fibrinolyticy activit of hemolytic streptococci. J Exp Med 1933; 58: 485-502
2. Mac Farlane RG, Pilling J.: Fibrinolytic activity in normal urine. Nature 1947;159:779
3. Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980;43:77-89 
4. Vassalli JD, Sappino AP, Belin D.: The plasminogen activator/plasmin system. J Clin Invest, 1991;88:1067-1072
5. Collen D, Lijnen HR.: Basic and clinical aspects of fibrinolysis and thombolysis. Blood, 1991; 78: 3114-3124
6. Sottrup-Jensen L, Claeys H, Zajdel M, Petersen TE, Magnusson S.: The primary structure of human plasminogen. En: Progress in Chemical Fibrinolysis and Thrombolysis, vol.3. Davidson JF, Rowan RM, Samama MM, Desnoyers PC (eds). Raven Press, New York, 1978; 191-209
7. Markus G, Evers JL, Hobiku FH.: Comparison of some properties of native (glu) and modified (lys) human plasminogen. J Biol Chem, 1978; 253:733-739
8. Bok RA, Mangel WF.: Quantitative characterization of the binding of plasminogen to intact fibrin clots, lysine-sepharose, and fibrin cleaved by plasmin. Biochemistry, 1985; 24:3279-3286
9. Lucas MA, Fretto LJ, Mckee PA.: The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem, 1983; 258:4249-4256
10. Robbins KC, Summaria L, Hsieh B, Shah RJ.: The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967; 242:2333-2342
11. Kluft C, Dooijewaard G, Emeis JJ.: Role of the contact system in fibrinolysis. Sem Thromb Hemost, 1987; 13:50-68
12. Collen D, Lijnen HR, Todd PA, Goa KL.: Tissue-type plasminogen activator.A review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs, 1989; 38:346-388
13. Hoylaerts M, Rijken DC, Lijen HR, Collen D.: Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem, 1982; 257:2912-2919
14. Lijnen HR, Zamarron C, Babler M, Winkler ME, Collen D.: Activation of plasminogen by prourokinase. I. Mechanism J Biol Chem, 1986; 261:1253-1258
15. Ichinose A. Mimuro J., Koide T., Aoki N.: Histidine-rich glycoprotein and alpha2-plasmin inhibitor in inhibition of plasminogen binding to fibrin. Thromb Res, 1984; 33:401-407
16. Sprengers DE, Kluft C.: Plasminogen activator inhibitors. Blood. 1987; 69:381-387
17. Loskutoff DJ, Sawdey M, Mimuro J.: Type 1 plasminogen activator inhibitor. Prog Hemost Thromb, 1989; 9:87-115
18. Colucci M, Paramo JA, Collen D.: Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fastacting inhibitor of plasminogen activator in vitro and in vivo. J Lab Clin Med 1986; 108 (1): 53-59
19. Páramo JA, Rocha E.: Fibrinolisis y trombosis venosa. Sangre 1992; 37 (Supl.3):88-94.
20. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D.: Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame shift mutation. N Engl J Med 1992; 327:1729-1733
21. Kruithof EKO.: Plasminogen activator inhibitors. A review. Enzyme, 1988; 40:113-121
22. Holmes WE, Nelles L, Lijnen HR, Collen D.: Primary structure of human alpha2-antiplasmin, a serine protease inhibitor (serpin). J Biol Chem, 1987; 262: 1659-1664.
23. Wiman B, Collen D.: On the mechanism of the reaction between human alpha2-antiplasmin and plasmin. J Biol Chem. 1979; 254: 9291-9297.
24. Páramo JA, Gascoine PS, Pring JB, Gaffney PJ.: The relative inhibition by ?2-antiplasmin and plasminogen activator inhibitor-1 of clot lysis in vitro. Fibrinolysis, 1990; 4: 169-175.
25. Sottrup-Jensen L, Stepanik TM, Kristensen T, et al.: Primary structure of human alpha2-macroglobulin. V. The complete structure. J Biol Chem, 1984; 259: 8318-8327.
26. Salvesen GS, Catanese JJ, Kress LF, Travis J.: Primary structure of the reactive site of human C1-inhibitor. J Biol Chem, 1985; 260: 2432-2436.
27. Colucci M, Páramo JA, Collen D.: Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest, 1985; 75: 818-824.
28. Wiman B, Collen D.: Molecular mechanism of phisiological fibrinolysis. Nature, 1978; 272: 549-550
29. Fleury V, Lijnen HR, Angles Cano E.: Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. J Biol Chem, 1993; 268: 18554-559
30. Plow EF, Félez J, Miles LA.: Cellular  regulation of fibrinolysis. Thromb Haemostas 1991; 66:32-36
31. Collen D, Bounameaux H, De Cook F, Lijnen HR, Verstraete M. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986; 73: 511-517
32. Tillet WS, Sherry S.: The effect in patients of streptococcal desoxyribonuclease on fibrinous, purulent and sanguinous pleural exudations. J Clin Invest 1949; 28:173-190.
33. Tillet WS, Johnson AJ.: The intavenous infusion of the streptoccocal fibrinolytic principle (streptokinase) into patients. J Clin Invest 1955; 34:169-185.
34. Chibber BAK, Castellino FJ.: Regulation of the streptokinase-mediated activation of human plasminogen by fibrinogen and chloride ions. J Biol Chem 1986; 261:5289-5295.
35. Marder VJ, Sherry S.: Thombolytic therapy. Current status. N Engl J Med, 1988; 318: 1512-1520 y 1585-1595.
36. Verstraete M.: Biochemical and clinical aspects of thrombolysis. Semin Hematol, 1978; 15: 35-54.
37. Gruppo italiano per lo Studio della Streptochinasi nell infarto Miocardico (GISSI).: Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet, 1986; 1: 397-402.
38. ISIS-2(Second International Study of Infarct Survival) Colaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17.187 cases of suspected acute myocardial infarction; ISIS-2. Lancet 1988; ii: 349-360
39. René A, Ron H.: Adult Respiratory Distress Syndrome After Streptokinase. Am J Cardiol 1992; 70:1632-1633.
40. Fears R, Ferres H, Glasgow E, Standring R, Hogg K, et al: Monitoring of Streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase Ig G. Br Heart J 1992; 68: 167-170.
41. Jalihal S, Morris GK: Antistreptokinase titres after intravenous streptokinase. Lancet 1990; 335:184-185
42. Garg Shaila, MD, Y.S. Chandrashekhar, MD, DM, Nanda Kumar.: Antistreptokinase Antibodies Before and After Streptokinase Therapy in Patients with Acute Myocardial Infarction from Areas Endemic for Streptococcal Infection and Influence on Reperfusion Rates. Am J Cardiol 1994; 74:187-189.
43. Barlow GH, Laazer L, Rueter A, Tribby I.: Production of plasminogen activator by tissue culture techniques. En: Paoletti R. Sherry (eds): Thrombosis and Urokinase. PP. 75-81, London Academic Press. Proceedings of the Serono Symposia, vol 9; 1977.
44. Walker JE, Ogston D.: The inhibition of tissue activator and urokinase by human plasma. Thromb Haemost, 1982, 47: 265.
45. Robbins KC.: The plasminogen-plasmin enzime system. En: Hemostasis and Thrombosis, 2ª De, eds. RW Colman et al. Philadelphia, Lippincot, 1987.
46. Marder VJ, Donahue JF, Bell WR et al. Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism. J Lab Clin Med 1978; 92: 721-729.
47. Summaria L, Arzadon L, Bernabe P, Robbins KC. The activation of plasminogen to plasmin by urokinase in the presence of the plasmin inhibitor trasylol. J Biol Chem 1975; 250: 2988-95.
48. Schneider P, Bachmann F, Sauser D. Urokinase: a short rewiew of its properties and of its metabolism. In: D´Angelo A, de. Urokinase: basic and clinical aspects. London: Academic Press, 1982; 1-15.
49. Duckert F.: Urokinase. En: Fibrinolytics and anti-fibrinolytics. Markwardt F de. Springer-Verlag, Berlín, Heildelberg, New York, 1978; pp: 209-229.
50. Astrup T, Permin PM.: Fibrinolysis in animal organism. Nature, 1974; 159: 681-682.
51. Levin EG.: Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme inhibitor complex. Proc Nat Acad Sci USA, 1983;80: 6804-6808.
52. Loscalzo J, Braunwald E. Tissue plasminogen activator. N Engl J Med 1988; 319: 925-931.
53. Dodd I, Nunn B, Robinson JH.: Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site. Thromb Haemost, 1988; 59: 523-528.
54. Ranby M, Bergsdorf N, Nilsson T.: Enzymatic properties of the one and two-chain form of tissue plasminogen activator. Thromb Res 1982; 27: 175-183.
55. Rijken DC, Hoylaerts M, Collen D.: Fibrinolytic properties of one-chain two-chain human extrinsic (tissue-type) plasminogen activator. Their Biol Chemistry, 1982; 257: 2920-2925.
56. Zamarron C, Lijnen HR, Collen D.: Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator. J Biol Chem, 1984; 259: 2080-2083.
57. Chesebro JH, Knatterud G, Roberts R et al. Thrombolysis in myocardial infarction (TIMI) Trial, phase I: A comparison betwen intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-154.
58. Granger CB, Califf RM, Topol EJ.: Thrombolytic therapy for acute myocardial infarction. A review. For Adis. Drug 44: 293-325, 1992.
59. Stump DC, Callif RM, Topol EJ, and the TAMI Study Group: Phar macodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation 80: 1222-1230, 1989.
60. Collen D, Lijnen HR, Todd PA.: Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs, 1989; 38(3): 346-388.
61. Tanswell P, Seifried E, Fenerer W, Rijken DC.: Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther, 1989; 46: 155-162.
62. Bugelski PJ Fong KL et al.: Uptake of human recombinant tissue type plasminogen activator by rat hepatocytes in vivo: an electron microscope autoradiographic study. Tromb Res, 1989; 53: 287-303.
63. Alteplase recombinant. En: Physicins´desk Reference. Medical Economics Data. Montvale. USA. 1993.
64. Collen D, Stump DC, Gold HK.: Thrombolytic therapy. Ann Red Med, 1988; 39: 405-423.
65. Monk JP, Heal RC. Anisoylated plasminogen streptokinase activator complex(APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction. Drugs 1987; 34: 25-49.
66. Kohnert U, Rudolph R, Verheijen JH, et al. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng. 1992; 66: 569-574.
67. Martin U, Bader R, Böhm E, et al. BM 06..022: a novel recombinant plasminogen activator. Cardiovasc Drug Rev. 1993; 11: 299-311.
68. Agnelli G. The pharmacological basis of thrombolytic therapy. In: Agnelli G, de. Thrombolysis Yearbook 1995. Amsterdam: Excerpta Medica; 1995: 31-61.
69. Martin U, Sponer G, Strein K. Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro. Blood Coagul Fibrinolysis. 1993; 4: 235-242.
70. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase duoble-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet.1995; 346: 329-336.
71. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation. 1995; 91: 2725-2732.
72. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double bolus reteplase and front-loaded, “accelerated” alteplase in patients with acute myocardial infarction. Submitted for publication.
73. Samama M, Horellou MH, Laaban JP, Conard J. Should thrombolytic therapy be used in pulmonary embolism? In: Fundamental and Clinical Fibrinolysis. FJ Castellino, PJ Gaffney, MM Samama, A Takada Eds. Excerpta Medica, Amsterdam 1987; 757:215-226.
74. Martin M, Fiebach BJO. Short-term ultrahigh streptokinase treatment of chronic arterial acclusions and acute deep vein thromboses. Semin Thromb Haemost 1991; 17:21-38.
75. Grimm W, Schwieder G, Wagner T. Deep vein thrombosis: methods of thrombolytic therapy compared. Biomedical Prog 1994; 7:3-7.) 75.Grimm W, Schwieder G, Wagner T. Deep vein thrombosis: methods of thrombolytic therapy compared. Biomedical Prog 1994; 7:3-7.
76. Van de Loo JC, Kriessmann A, Trubestein G et al. Controlled multicenter pilot study of urokinase, heparin and streptokinase in deep vein thrombosis. Thromb Haemost 1983; 50:660-5.
77. Goldhaber  SZ, Polak JF, Feldstein ML et al. Efficacy and safety of repeated boluses of urokinase in the treatment of deep venous thrombosis. Am J Cardiol 1994; 73:75-79
78. Turpie AGG, Levine MN, Hirsh J et al. Tissue plasminogen activator versus heparin in deep vein thrombosis. Results of a randomized trial. Chest 1990; 97:172S-175S
79. Goldhaber SZ, Meyerovitz MF, Green D et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 1990; 88:235-40
80. Zimmerman R, Gürsoy A, Horn A et al. Fibrinolytic therapy of deep vein thrombosis with continuous intravenous infusion of a recombinant tissue plasminogen activator. Semin Thromb Haemost 1991; 17:48-54
81. Marder VJ, Brenner B, Totterman S et al. Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. J Lab Clin Med 1992; 119:485-495
82. Bounameaux H, Banga JD, Bluhmki E et al. Double-blind randomized comparison of systemic continuous infusion of 0.25 versus 0.50 mg/kg/24h of alteplase over 3 to 7 days of treatment of deep venous thrombosis in heparinized patients: results of the European Thrombolysis with rt-PA in venous Thrombosis (ETTT) Trial. Thromb Haemost 1992; 67:306-9
83. Goldhaber SZ. Contemporary pulmonary embolism thrombolysis. Chest 1995; 1:45S-51S
84. Verstraete M, Miller GAH, Bounameaux H et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77:353-60
85. PIOPED Investigators. Value of the V/Q scan in acute pulmonary embolism. Results of the Prospective Investigation of Pulmonary Embolism Diagnosis(PIOPED). J Am Med Assoc 1990; 263:2753-9
86. Meyerovitz M. How to maximize the safety of coronary and pulmonary angiography in patients receiving thrombolytic therapy. Chest 1990; 97:132S-135S
87. Levine MN, Hirsh J, Weitz J et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.Chest 1990; 98:1473-9
88. Diehl JL, Meyer G, Igual J et al. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. Am J Cardiol 1992; 70:1477-80
89. Goldhaber SZ, Agnelli G, Levine MN on behalf of The Bolus Alteplase Pulmonary Embolism Group. Reduced dose bolus alteplase versus conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomized trial. Chest 1994; 106:718-24
90. Sors H, Pacouret G et al. Hemodynamic effects of bolus versus two hour infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994; 106:712-14
91. Goldhaber SZ, Feldstein ML, Sors H. Two trials of reduced dose bolus alteplase in the treatment of pulmonary embolism. An overview. Chest 1994; 106:725-26
92. Wardlaw JM, Warlow CP. Thrombolysis in acute ischemic stroke: does it work ? Stroke 1992; 23:1826-1839
93. Del Zoppo GJ. Thrombolysis therapy in stroke. In: Thrombolysis Yearbook. Ed. G Agnelli. Excerpta Medica, Amsterdam 1994;113-135
94. Fibrinolytic Therapy Trialist (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbility results from all randomized trials of more than 1000 patients. Lancet 1994; 343:311-22
95. Martin GV, Kennedy JW. Elección del agente trombolítico (capítulo 3). En Manejo del Infarto Agudo de Miocardio. Ed. por Julian D y Braunwald E.- W.B. Saunders Company, Barcelona 1996; 75-112 
96. Dalen JE, Hirsh J. Fourth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1995; 108:401S423S 
97. Daniels LB, Parker JA, Patel SR, Gronstein F, Goldhaber SZ. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997; 80:184-188
98. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombosis and embolic stroke. Ann Neurol 1992; 32:78-86
99. The Multicenter Acute Stroke Trial - Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335:145-150
100. Donnan GA, Davis SM, Chambers BR, et at. Trials of streptokinase in severe acute ischemic stroke. Lancet 1995; 345:578-579
101. Multicenter Acute Stroke Trial - Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346:1509-1514
102. The European Cooperative Acute Stroke Study (ECASS). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemospheric stroke. JAMA 1995; 274:1017-1025
103. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-1587
104. Grotta J. t-PA - The best current option for most patients. N Engl J Med 1997; 337:1310-1313
105. Caplan LR, Mohr JP, Kistler JP, Korohetz W. Thrombolylis - Not a panacea for ischemic stroke. N Engl J Med 1997; 337:1309-1310
106. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: the STILE trial. Ann Surg 1994; 220:251-268
107. Ouriel K, Veith FJ, Sasahara AA, for the Thrombolysis Or Peripheral Arterial Surgery (TOPAS) investigators. N Engl J Med 1998; 338:1105-1111
108. Ouriel K, Veith FJ. Acute lower limb ischemia: determinants of outcome. Surgery 1998; 124:336-342
109. Manteiga R, Souto C, Altés A, et al. Short-.course thrombolysis as the first line of therapy for cardiac valve thrtombosis. J Thorac Cardiovasc Surg 1998; 115:780-784
110. Delacrétaz E, Beer J, Fleisch M, et al. Low-dose thrombolysis for thrombosed prosthetic heart valve. Chest 1996; 110:574-575
111. Lengyel M, Fuster V, Keltai M, et al. Guidelines for management of left-sided prosthetic valve thrombosis: a role for thrombolytic therapy. Consensus Conference on Prosthetic Valve Thrombosis. J Am Coll Cardiol 1997; 30:1521-1526
112. Renzulli A, Vitale N, Caruso A, et al. Thrombolysis for prosthetic valve thrombosis: indications and results. J Heart Valve Dis 1997; 6:212-218
113. Agrawal D, Dubey S, Saket B, et al. Thrombolylic therapy for prosthetic valve thrombosis in Third World countries. Indian Heart J 1997; 49:383-386
114. Jichici D, Frank JL. Thrombolytic therapy in neurointensive care. Crit Care Clin 1997; 13:201-227
115. Luciano R, Tortorolo L, Chiaretti A, et al. Intraventricular streptokinase infusion in acute post-haemorrhagic hydrocephalus. Intensive Care Med 1998; 24:526-529
116. Azkárate B, Mintegi I, Reviejo K, et al. Tratamiento fibrinolítico local en las hemorragias intraventriculares. Med Intensiva 1998; 22:275-277 
117. Hayes DL, Spittell PC. Thrombotic venous complications of permanent pacing. En Recent Advances in Cardiac Pacing: Goals for the 21st Century. Vol. 4, editado por S. serge Barold y J. Mugica, Armonk, NY, Futura Publisshing Co, 1998; 215-236
118. Cooper CJ, Dweik R, Gabbay S. Treatment of pacemaker-associated right atrial thrombus with 2-hour rt-PA infusion. Am Heart J 1993; 126:228-229
119. Sunder SK, Ekong EA, Sivalingam K, et al. Superior vena cava thrombosis due to pacing electrodes: successfull treatment with combined thrombolysis and angioplasty. Am Heart J 1992; 123:790-792
120. Moulton JS, Benkert RE, Weisiger KH, Chambers JA. Treatment od complicated pleural fluid collections with image-guided drainage and intracavitary urokinase. Chest 1995; 108:1252-1259.